CSBio CSBio

X
[{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicines","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze\u00ae in The US","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ohara Pharmaceutical"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SERB Receives Positive CHMP Opinion for Voraxaze\u00ae (Glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Serb"},{"orgOrder":0,"company":"Rising Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address Lead Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Rising Pharmaceuticals"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meridian Medical Technologies, Kindeva Drug Delivery\u2019s Global Health Security Division, Awarded Contract to Supply DuoDote\u00ae","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Meridian Medical Technologies"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent antidote.

            Lead Product(s): Atropine,Pralidoxime Chloride

            Therapeutic Area: Pharmacology/Toxicology Product Name: DuoDote

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ASPR

            Deal Size: $9.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement November 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Rising Pharmaceuticals

            Contact Supplier
            • Development Update
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.

            Lead Product(s): Edetate Calcium Disodium

            Therapeutic Area: Pharmacology/Toxicology Product Name: Edetate Calcium Disodium-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further systemic damage.

            Lead Product(s): Glucarpidase

            Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: BTG Specialty Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.

            Lead Product(s): Glucarpidase

            Therapeutic Area: Pharmacology/Toxicology Product Name: Megludase

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: BTG Specialty Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KLOXXADOTM contains twice as much naloxone per spray as Narcan® Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic.

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Pharmacology/Toxicology Product Name: Kloxxado

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.

            Lead Product(s): Glucarpidase

            Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Serb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY